PR Newswire Clinical TrialsOriginal article
Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
Phase 3bexicaserinPositive
AI Analysis
Summary
Lundbeck announced the last patient was randomized in DEEp OCEAN, a Phase III global trial evaluating investigational molecule bexicaserin for treating seizures associated with developmental and epileptic encephalopathies.
Clinical Trial Data
Phase
3
Outcome Details
last patient randomized in DEEp OCEAN trial
Importance:5/10
Sentiment:
0.40
Phase 3epilepsydevelopmental encephalopathytrial milestoneLundbeck
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on July 20, 2026 7:46 AM